At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 12 enrolled
Drug / intervention
Nebivolol +1 moredrug
Likely dose
Nebivolol 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Nebivolol on Forearm Vasodilation, Nitric Oxide Bioavailability, and Oxidative Stress in Patients With Stage 1/2 Hypertension
In Brief
A Phase 3 clinical trial evaluating Nebivolol and Metoprolol ER (TM) for Hypertension. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another beta blocker, extended-release metoprolol, at a range of doses. Its purpose is to study the mechanism of action of nebivolol on forearm blood flow, nitric oxide availability and other biomarkers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedApr 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedApr 1, 2008
Enrollment StartNov 1, 2007
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.3 years ago
Interventions
Nebivololdrug
nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
Metoprolol ER (TM)drug
Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration